Integrity Alliance LLC. Buys Shares of 9,605 Axsome Therapeutics, Inc. $AXSM

Integrity Alliance LLC. bought a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 9,605 shares of the company’s stock, valued at approximately $1,754,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GAMMA Investing LLC grew its stake in Axsome Therapeutics by 65.4% in the fourth quarter. GAMMA Investing LLC now owns 268 shares of the company’s stock valued at $49,000 after purchasing an additional 106 shares in the last quarter. Farther Finance Advisors LLC lifted its position in shares of Axsome Therapeutics by 602.6% in the fourth quarter. Farther Finance Advisors LLC now owns 274 shares of the company’s stock worth $50,000 after buying an additional 235 shares during the last quarter. Optiver Holding B.V. lifted its position in shares of Axsome Therapeutics by 82.3% in the third quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock worth $35,000 after buying an additional 130 shares during the last quarter. Essex Investment Management Co. LLC acquired a new stake in shares of Axsome Therapeutics in the third quarter worth about $38,000. Finally, Advisory Services Network LLC acquired a new stake in shares of Axsome Therapeutics in the third quarter worth about $40,000. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Insider Activity

In related news, COO Mark L. Jacobson sold 4,517 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $227.94, for a total transaction of $1,029,604.98. Following the completion of the transaction, the chief operating officer owned 4,517 shares of the company’s stock, valued at approximately $1,029,604.98. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ari Maizel sold 7,500 shares of the business’s stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $182.42, for a total value of $1,368,150.00. Following the transaction, the insider directly owned 7,500 shares of the company’s stock, valued at $1,368,150. This represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 12,250 shares of company stock valued at $2,450,921 in the last three months. 20.60% of the stock is owned by insiders.

Axsome Therapeutics Price Performance

NASDAQ AXSM opened at $234.52 on Thursday. Axsome Therapeutics, Inc. has a twelve month low of $96.09 and a twelve month high of $238.56. The company has a debt-to-equity ratio of 2.27, a quick ratio of 1.32 and a current ratio of 1.39. The stock has a market capitalization of $12.07 billion, a PE ratio of -62.87 and a beta of 0.59. The stock has a 50-day simple moving average of $192.56 and a 200 day simple moving average of $174.16.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.41). Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.The business had revenue of $191.20 million for the quarter, compared to analyst estimates of $191.10 million. Axsome Therapeutics’s revenue was up 57.4% on a year-over-year basis. Research analysts anticipate that Axsome Therapeutics, Inc. will post -2.14 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on AXSM. Royal Bank Of Canada boosted their price target on Axsome Therapeutics from $242.00 to $302.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 5th. Wolfe Research began coverage on Axsome Therapeutics in a research report on Monday, February 23rd. They issued an “outperform” rating and a $230.00 price target for the company. Truist Financial raised Axsome Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. TD Cowen reaffirmed a “buy” rating on shares of Axsome Therapeutics in a research report on Friday, May 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $272.00 price target on shares of Axsome Therapeutics in a research report on Monday, May 4th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $251.26.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.